Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report.
Date
2024-07-01ICR Author
Author
John, A
Vick, J
Sarker, S
Middleton, E
Cartwright, E
Manickavasagar, T
McMahon, D
Tokaca, N
Popat, S
Type
Journal Article
Metadata
Show full item recordAbstract
Neurocognitive adverse events (NAEs) have been reported in up to 60% of patients on lorlatinib, a potent central nervous system-active ALK inhibitor. Manifestations may include psychotic, mood, speech, and cognitive symptoms. Current guidance recommends permanent discontinuation of lorlatinib in cases of grade IV NAEs. Here, we report a case of successful rechallenge of dose-reduced lorlatinib after recovery of grade IV psychosis in a patient with ALK-positive NSCLC.
Collections
Subject
ALK
Adverse event
Case report
Lorlatinib
Non–small cell lung cancer
Psychosis
Language
eng
Date accepted
2024-05-12
License start date
2024-07-01
Citation
JTO Clinical and Research Reports, 2024, 5 (7), pp. 100689 -
Publisher
ELSEVIER